Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Open access
Martin, Thomas, Baz, Rachid, Benson, Don M., Lendvai, Nikoletta, Wolf, Jeffrey, Munster, Pamela, Lesokhin, Alexander M., Wack, Claudine, Charpentier, Eric, Campana, Frank, Vij, Ravi · 2017 · Blood

Abstract

Key Points: Isatuximab (anti-CD38 monoclonal antibody) given with lenalidomide/ dexamethasone is active in heavily pretreated relapsed/refractory myeloma Overall, the safety profile of this combination is similar to the characteristic safety profiles of the individual agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2016-09-740787

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 22

  1. Rajkumar, 2012, Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?, 354
  2. Eshaghian, 2012, Multiple myeloma: improved outcomes with new therapeutic approaches, Curr Opin Support Palliat Care, 6, 330, 10.1097/SPC.0b013e3283565c56 · DOI
  3. Palumbo, 2012, Continuous lenalidomide treatment for newly diagnosed multiple myeloma, N Engl J Med, 366, 1759, 10.1056/NEJMoa1112704 · DOI · Paper page
  4. Kumar, 2008, Improved survival in multiple myeloma and the impact of novel therapies, Blood, 111, 2516, 10.1182/blood-2007-10-116129 · DOI · Paper page
  5. San-Miguel, 2016, Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial, Lancet Haematol, 3, e506, 10.1016/S2352-3026(16)30147-8 · DOI
  6. Siegel, 2016, VANTAGE 095: an international, multicenter, open-label study of vorinostat (MK-0683) in combination with bortezomib in patients with relapsed and refractory mulltiple myeloma, Clin Lymphoma Myeloma Leuk, 16, 329, 10.1016/j.clml.2016.02.042 · DOI
  7. Kumar, 2012, Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study [published correction appears in Leukemia. 2012;26(5):1153], Leukemia, 26, 149, 10.1038/leu.2011.196 · DOI · Paper page
  8. Lonial, 2016, Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma, Expert Opin Biol Ther, 16, 1291, 10.1080/14712598.2016.1221920 · DOI
  9. Palumbo, 2016, Daratumumab, bortezomib and dexamethasone for multiple myeloma, N Engl J Med, 375, 754, 10.1056/NEJMoa1606038 · DOI · Paper page
  10. Roguska, 1994, Humanization of murine monoclonal antibodies through variable domain resurfacing, Proc Natl Acad Sci USA, 91, 969, 10.1073/pnas.91.3.969 · DOI · Paper page
  11. Martin, 2015, A dose finding phase II trial of isatuximabtuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed/refractory multiple myeloma [abstract], Blood, 126, 10.1182/blood.V126.23.509.509 · DOI
  12. Durie, 2006, International uniform response criteria for multiple myeloma [published correction appears in Leukemia. 2006;21:1134; Leukemia. 2006;20(12):2220], Leukemia, 20, 1467, 10.1038/sj.leu.2404284 · DOI · Paper page
  13. Xu, 2013, Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1, Cancer Immunol Immunother, 62, 1637, 10.1007/s00262-013-1466-y · DOI
  14. Mitsiades, 2013, Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma, Crit Rev Oncol Hematol, 88, S5, 10.1016/j.critrevonc.2013.05.014 · DOI
  15. Chan, 2014, Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy, Clin Exp Immunol, 175, 49, 10.1111/cei.12196 · DOI
  16. Rajkumar, 2011, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, Blood, 117, 4691, 10.1182/blood-2010-10-299487 · DOI · Paper page
  17. João, 2015, Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center, Ann Hematol, 94, 97, 10.1007/s00277-014-2164-3 · DOI
  18. Dimopoulos, 2014, Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma, Blood Cancer J, 4, e257, 10.1038/bcj.2014.77 · DOI
  19. Yang, 2013, Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials, PLoS One, 8, e64354, 10.1371/journal.pone.0064354 · DOI
  20. San Miguel, 2013, Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial, Lancet Oncol, 14, 1055, 10.1016/S1470-2045(13)70380-2 · DOI · Paper page
  21. Richardson, 2015, Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study, Lancet Haematol, 2, e516, 10.1016/S2352-3026(15)00197-0 · DOI
  22. Plesner, 2016, Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma, Blood, 128, 1821, 10.1182/blood-2016-07-726729 · DOI

Cited by

See all 166

Metadata

Authors
Martin, T., Baz, R., Benson, D. M., Lendvai, N., Wolf, J., Munster, P., Lesokhin, A. M., Wack, C., Charpentier, E., Campana, F., & Vij, R.
Venue
Blood
Published
2017-06-22
Volume
129
Issue
25
Pages
3294-3303
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2612430336
Cited by
166
References
9
FWCI
18.46
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2016-09-740787
The paper
Martin, T., Baz, R., Benson, D. M., Lendvai, N., Wolf, J., Munster, P., Lesokhin, A. M., Wack, C., Charpentier, E., Campana, F., & Vij, R. (2017). A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. https://doi.org/10.1182/blood-2016-09-740787

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.